Published online Nov 27, 2021. doi: 10.4254/wjh.v13.i11.1791
Peer-review started: February 9, 2021
First decision: May 13, 2021
Revised: May 18, 2021
Accepted: October 12, 2021
Article in press: October 12, 2021
Published online: November 27, 2021
Patients with cirrhosis are at risk of exercise limitations due to progressive limitations related to liver dysfunction. Sarcopenia and cirrhotic cardiomyopathy may be possible related factors. The six-minute walking test (6MWT) is a known simple and practical tool used to evaluate patients with cardiopulmonary disease.
In face of limited diagnosis tools focused on exercise capacity, we purposed to evaluate the role of 6MWT in this population.
The aim of our study was to analyzed 6MWT performance in patients with liver cirrhosis to determine if it associates with mortality.
We analyzed 6MWT performance in 106 cirrhotic patients. They were evaluated in the outpatient setting with 6MWT and follow up for one year. Hepatic decompensation and mortality were documented.
This cohort had a mean age of 51 years and 56% male; patients were staged as Child A in 21.7%, B 66%, and C 12.3%. Walk distance inversely correlated with Child scores, and was significantly reduced as Child stages progress. Patients who died (10.4%) showed a shorter mean 6MWD (P = 0.006). Low 6MWD was an independent predictor of mortality (P = 0.01).
6MWT is a noninvasive inexpensive test whose result is related to Child scores and mortality.
It is a useful, simple, practical test that can be incorporated into cirrhotic evaluation due to its relation with mortality for closer monitoring and potential early intervention.